| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7476689 | ZYLA | Therapeutic compositions for intranasal administration which include KETOROLAC |
Oct, 2012
(11 years ago) | |
| US6333044 | ZYLA | Therapeutic compositions for intranasal administration which include KETOROLAC® |
Dec, 2018
(5 years ago) | |
Sprix is owned by Zyla.
Sprix contains Ketorolac Tromethamine.
Sprix has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Sprix are:
- US7476689
- US6333044
Sprix was authorised for market use on 14 May, 2010.
Sprix is available in spray, metered;nasal dosage forms.
Sprix can be used as treatment of inflammation and pain using a nasal spray of ketorolac tromethamine, treatment of pain using a nasal spray of ketorolac tromethamine.
The generics of Sprix are possible to be released after 25 December, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 14, 2013 |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 14 May, 2010
Treatment: Treatment of pain using a nasal spray of ketorolac tromethamine; Treatment of inflammation and pain using a nasal spray of ketorolac tromethamine
Dosage: SPRAY, METERED;NASAL
SPRIX family patents
